CARILION CLINIC
Antimicrobial Stewardship

Patient Education: Remdesivir (Veklury®) Outpatient Use

NIH Treatment Recommendations / Pinetree Study

Criteria for Use:

- Meets ALL of the following:
  - Adult or pediatric patient weighing at least 3.5 kg
  - Positive COVID-19 test and **only mild to moderate disease**
  - Within **7 days of symptom onset** (not from COVID-19 test result)
  - High risk of progression to severe disease

What is Remdesivir:

- Remdesivir is an antiviral that is FDA approved for the treatment of COVID-19.
- Using remdesivir is recommended in recent National Institutes of Health guidelines based on a new study.
- This study of non-hospitalized patients with mild to moderate COVID-19 within 7 days of symptom onset, showed IV remdesivir resulted in a significant reduction in hospitalizations and deaths compared to placebo.
- Remdesivir is expected to be active against currently circulating COVID-19 variants.

Dosing: 200 mg IV x 1 day, then 100 mg IV x 2 days

No renal or hepatic adjustments are necessary.

Adverse Effects/Precautions

- The most common significant adverese effects are infusion-related reactions which include: low blood pressure, nausea, vomiting, sweating, and shivering.
  - **Patients will be monitored for infusion reactions 1 hour after the end of the infusion.**
- Increases in levels of liver enzymes have been seen in people who have received remdesivir, which may be a sign of inflammation or damage to cells in the liver.
- Other adverse effects are possible.

Pregnancy and Lactation

- Information related to use in pregnant patients is available from small studies and case reports and therefore it may be used after risk/benefit discussion with OB provider.

Drug Interactions:

- Chloroquine and hydroxychloroquine **may diminish therapeutic** effects of remdesivir and are not recommended to be used with remdesivir.

Last Updated: 12/7/2022